Computational pipeline for the PGV-001 neoantigen vaccine trial

Alex Rubinsteyn, Julia Kodysh, Isaac Hodes, Sebastien Mondet, Bulent Arman Aksoy, John P. Finnigan, Nina Bhardwaj, Jeffrey Hammerbacher

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


This paper describes the sequencing protocol and computational pipeline for the PGV-001 personalized vaccine trial. PGV-001 is a therapeutic peptide vaccine targeting neoantigens identified from patient tumor samples. Peptides are selected by a computational pipeline that identifies mutations from tumor/normal exome sequencing and ranks mutant sequences by a combination of predicted Class I MHC affinity and abundance estimated from tumor RNA. The personalized genomic vaccine (PGV) pipeline is modular and consists of independently usable tools and software libraries. We hope that the functionality of these tools may extend beyond the specifics of the PGV-001 trial and enable other research groups in their own neoantigen investigations.

Original languageEnglish
Article number1807
JournalFrontiers in Immunology
Issue numberJAN
StatePublished - 18 Jan 2018


  • Computational pipeline
  • Genomics
  • Immunoinformatics
  • Neoantigens
  • Personalized vaccine


Dive into the research topics of 'Computational pipeline for the PGV-001 neoantigen vaccine trial'. Together they form a unique fingerprint.

Cite this